Twist Bioscience agrees to governance reforms in proposed shareholder lawsuit settlement
TWST•Twist Bioscience reached a proposed settlement of shareholder derivative litigation, subject to court approval. It calls for governance reforms within 45 days of approval and $1 million in attorneys’ fees and expenses paid by insurers for individual defendants.
1. Proposed settlement
Under an agreement dated October 15, 2026, Twist Bioscience reached a proposed settlement of shareholder derivative litigation, subject to court approval. The Delaware federal court is scheduled to consider final approval and dismissal with prejudice at a January 22, 2027, hearing.
2. Reforms and fees
The proposed settlement requires the board to adopt corporate governance reforms within 45 days of final court approval. Insurers for the individual defendants would pay $1 million in attorneys’ fees and expenses, including awards of up to $2,000 for each of two plaintiffs.
